Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies has received a grant of $600,000 from the National Institutes of Health (NIH) to study the probability of developing a vaccine against infection by human papilloma virus (HPV).
Subscribe to our email newsletter
In contradiction to the two approved HPV vaccines that target approximately 70% of HPV strains, Dynavax Technologies is into developing a vaccine that provides immunity to nearly all cancer-causing strains of HPV.
Dynavax Technologies is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious diseases.
Dynavax Technologies’ lead product candidate Heplisav is an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines.
Heplisav is known to combine hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.